Current European practice in pediatric myeloablative conditioning

Vettenranta, Kim

doi:10.1038/bmt.2008.47

Cited by 15 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunosuppressive effect was required to ensure engraftment. 4,27,28 Historically, combination of CY (Cy 120 mg/kg) and TBI was the most used conditioning regimen. 25,28,29 Radiation-free regimen had been proven effective for eradication of leukemia and sufficiently immunosuppressive for engraftment in HLA-matched sibling transplantation.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3] Even though AML prognostic or risk classification is worldwide based on karyotype and molecular markers, the indication of HSCT in CR1 differs from one cooperative group to the other. 4 Until recently, we-the French group-indicated allogeneic HSCT for all patients-except those with t(15;17) or t(8;21)-in CR1 and having a sibling donor. 2,5 In the same period, indications of HSCT were extended to patients without a sibling donor and presenting with poor prognosis AML, that is, mixed lineage leukemia rearrangement (or 11q23 mutation), monosomy 7, t(6;9), FLT3-TID.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Berranger

Cousien

Petit

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic hematopoietic SCT (HSCT) appears to be an efficient tool to cure high-risk AML in first CR but the choice between BUbased or TBI-based conditioning regimens still remains controversial. In order to analyze the impact of conditioning regimen on long-term survival, we conducted a retrospective analysis from French registry data including all consecutive patients under 18 years old (n ¼ 226) from 1980 to 2004 transplanted for AML in CR1 from sibling (n ¼ 142) or matched unrelated donors and given either TBI-1200 cGy and CY 120 mg/kg (TBI-Cy, n ¼ 84) or BU 16 mg/kg and CY 200 mg/kg (BuCy200, n ¼ 142). Patient subgroups were comparable for all criteria except for median age at diagnosis and HSCT and for donor type. Both 5-year OS and disease-free survival (DFS) were significantly better in BuCy200 group (P ¼ 0.02 and 0.005, respectively). In multivariate analysis, both HLA matching and BuCy200 appeared as good prognostic factors for treatment-related mortality and DFS. Grade 2-4 acute GvHD and chronic GvHD rates were statistically higher in TBI-Cy group than in Bu-Cy200 one with a RR at 2 (P ¼ 0.002). In total, Bu-Cy200 conditioning regimen gives better outcome compared with TBI-Cy irrespective of the stem cell source and the donor type.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Berranger

Cousien

Petit

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…However, TBI proved to be superior as far as overall survival (OS), disease-free survival (DFS), graft vs. host reaction (GvHR) and VOD incidence were concerned [5,6,13,17,28]. Therefore, total body irradiation has remained the cornerstone of conditioning regimens in pediatric hematologic diseases [30] despite the risk of possible late consequences.…”

Section: Introductionmentioning

confidence: 99%

Total Body Irradiation (TBI) in Pediatric Patients

et al. 2010

View full text Add to dashboard Cite

As severe late sequelae after TBI, we observed 2 secondary malignancies in 11 patients who survived in excess of 36 months. However, long-term morbidity is moderate following treatment with the fractionated TBI at the low-dose rate that was generally used here. Conditioning for bone marrow transplantation without radiation is an attractive option, but is not sufficiently effective to completely replace TBI for the most common pediatric indications.

show abstract

“…Busulfan and cyclophosphamide are the most administered drugs [37]. Also, treosulphan and fludarabine containing reduced intensity conditioning regimens (RIC) have recently begun to be used with minimal TRM, but still need more prospective trials for recommendation [38].…”

Section: Postremission Therapymentioning

confidence: 99%

Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients

Seval

Özcan

2015

JCM

View full text Add to dashboard Cite

The objectives of this review were to discuss standard and investigational treatment strategies for adolescent and young adult with acute myeloid leukemia, excluding acute promyelocytic leukemia. Acute myeloid leukemia (AML) in adolescent and young adult patients (AYAs) may need a different type of therapy than those currently used in children and older patients. As soon as AML is diagnosed, AYA patient should be offered to participate in well-designed clinical trials. The standard treatment approach for AYAs with AML is remission induction chemotherapy with an anthracycline/cytarabine combination, followed by either consolidation chemotherapy or stem cell transplantation, depending on the ability of the patient to tolerate intensive treatment and cytogenetic features. Presently, continuing progress of novel drugs targeting specific pathways in acute leukemia may bring AML treatment into a new era.

show abstract

Current European practice in pediatric myeloablative conditioning

Cited by 15 publications

References 33 publications

Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Total Body Irradiation (TBI) in Pediatric Patients

Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients

Contact Info

Product

Resources

About